Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty
PHASE1CompletedINTERVENTIONAL
Enrollment
13
Participants
Timeline
Start Date
March 1, 2021
Primary Completion Date
December 31, 2021
Study Completion Date
June 29, 2022
Conditions
Prosthetic Joint Infection
Interventions
DRUG
TNP-2092
TNP-2092 for injection 100mg/vial
Trial Locations (1)
19107
Rothman Orthopedic Institute, Philadelphia
All Listed Sponsors
lead
TenNor Therapeutics Limited
INDUSTRY
NCT04294862 - Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty | Biotech Hunter | Biotech Hunter